Theravance Biopharma
TBPH
TBPH
121 hedge funds and large institutions have $431M invested in Theravance Biopharma in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 35 increasing their positions, 47 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
22% less capital invested
Capital invested by funds: $552M → $431M (-$121M)
26% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 47
Holders
121
Holding in Top 10
4
Calls
$22K
Puts
$23K
Top Buyers
| 1 | +$8.97M | |
| 2 | +$2.31M | |
| 3 | +$1.5M | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.47M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.45M |
Top Sellers
| 1 | -$7.4M | |
| 2 | -$7.21M | |
| 3 | -$3.4M | |
| 4 |
Jane Street
New York
|
-$3.03M |
| 5 |
NM
Newtyn Management
New York
|
-$2.3M |